The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Diverse Psychotomimetics Act Through a Common Signaling Pathway
Abstract
Three distinct classes of drugs: dopaminergic agonists (such as D-amphetamine), serotonergic agonists (such as LSD), and glutamatergic antagonists (such as PCP) all induce psychotomimetic states in experimental animals that closely resemble schizophrenia symptoms in humans. Here we implicate a common signaling pathway in mediating these effects. In this pathway, dopamine- and an adenosine 3′,5′-monophosphate (cAMP)–regulated phospho-protein of 32 kilodaltons (DARPP-32) is phosphorylated or dephosphorylated at three sites, in a pattern predicted to cause a synergistic inhibition of protein phosphatase–1 and concomitant regulation of its downstream effector proteins glycogen synthesis kinase–3 (GSK-3), cAMP response element–binding protein (CREB), and c-Fos. In mice with a genetic deletion of DARPP-32 or with point mutations in phosphorylation sites of DARPP-32, the effects of D-amphetamine, LSD, and PCP on two behavioral parameters—sensorimotor gating and repetitive movements—were strongly attenuated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
A functional neuroanatomy of hallucinations in schizophrenia
Silbersweig, D. A., Stern, E., Frith, C., Cahill, C., Holmes, A., Grootoonk, S., Seaward, J., McKenna, P., Chua, S. E., Schnorr, L., et al. (1995) · Nature · doi:10.1038/378176a0 · Cited by 906
The Neurobiology of Slow Synaptic Transmission
Greengard, P. (2001) · Science · doi:10.1126/science.294.5544.1024 · Cited by 867
Self-citationIncreased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 803
Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence
Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.237 · Cited by 688
Hemmings, H. C., Greengard, P., Tung, H. Y. L., & Cohen, P. (1984) · Nature · doi:10.1038/310503a0 · Cited by 614
Self-citationSchizophrenia: Diverse Approaches to a Complex Disease
Sawa, A., & Snyder, S. H. (2002) · Science · doi:10.1126/science.1070532 · Cited by 597
Amphetamine Psychosis: A "Model" Schizophrenia Mediated by Catecholamines
SNYDER, S. H. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.1.61 · Cited by 587
Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons
Bibb, J. A., Snyder, G. L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A. A., Tsai, L.-H., Kwon, Y. T., Girault, J.-A., Czernik, A. J., et al. (1999) · Nature · doi:10.1038/45251 · Cited by 552
Self-citation
Cited by
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Beaulieu, J.-M., Sotnikova, T. D., Yao, W.-D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., & Caron, M. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307921101 · Cited by 793
Valjent, E., Pascoli, V., Svenningsson, P., Paul, S., Enslen, H., Corvol, J.-C., Stipanovich, A., Caboche, J., Lombroso, P. J., Nairn, A. C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408305102 · Cited by 614
Self-citationRealistic expectations of prepulse inhibition in translational models for schizophrenia research
Swerdlow, N. R., Weber, M., Qu, Y., Light, G. A., & Braff, D. L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1072-4 · Cited by 529
Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia
Meyer, U., Feldon, J., Schedlowski, M., & Yee, B. K. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.10.012 · Cited by 494
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
The Akt–GSK-3 signaling cascade in the actions of dopamine
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.02.006 · Cited by 419
Toward a neurobiology of delusions
Corlett, P. R., Taylor, J. R., Wang, X.-J., Fletcher, P. C., & Krystal, J. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.007 · Cited by 394
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Jope, R., & Roh, M.-S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382
Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs
Gould, T. D., & Manji, H. K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300731 · Cited by 375
Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., & D’Souza, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.985 · Cited by 317
GSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
Modeling madness in mice: one piece at a time
Arguello, P. A., & Gogos, J. A. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.023 · Cited by 309
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
López-Giménez, J. F., & González-Maeso, J. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_478 · Cited by 299
The role of dopamine in bipolar disorder
Cousins, D. A., Butts, K., & Young, A. H. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00760.x · Cited by 291
Svenningsson, P., Bateup, H., Qi, H., Takamiya, K., Huganir, R. L., Spedding, M., Roth, B. L., McEwen, B. S., & Greengard, P. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05952.x · Cited by 289
Self-citationMolecular Mechanisms of Schizophrenia
Lang, U. E., Puls, I., Müller, D. J., Strutz-Seebohm, N., & Gallinat, J. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110430 · Cited by 281
Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56δ subunit
Ahn, J.-H., McAvoy, T., Rakhilin, S. V., Nishi, A., Greengard, P., & Nairn, A. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611532104 · Cited by 264
Self-citationHow can drug discovery for psychiatric disorders be improved?
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., et al. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2217 · Cited by 240
Self-citationFrom prediction error to psychosis: Ketamine as a pharmacological model of delusions
Corlett, P. R., Honey, G. D., & Fletcher, P. C. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077716 · Cited by 227
Ogden, C. A., Rich, M. E., Schork, N. J., Paulus, M. P., Geyer, M. A., Lohr, J. B., Kuczenski, R., & Niculescu, A. B. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001547 · Cited by 221
“34 is a downstream target of the DARPP-32 pathway”
BackgroundDopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes
Tost, H., Alam, T., & Meyer-Lindenberg, A. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.06.005 · Cited by 160
Griebel, G., Stemmelin, J., Lopez-Grancha, M., Boulay, D., Boquet, G., Slowinski, F., Pichat, P., Beeské, S., Tanaka, S., Mori, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54557-5 · Cited by 97
de Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
Kapfhamer, D., Berger, K. H., Hopf, F. W., Seif, T., Kharazia, V., Bonci, A., & Heberlein, U. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1292-10.2010 · Cited by 71
“Conversely, certain psychosis-inducing drugs (amphetamine, D-lysergic acid diethylamide, or phencyclidine) that attenuate PPI in rodents also inhibit GSK3 activity (Svenningsson et al., 2003).”
BackgroundPascoli, V., Valjent, E., Corbillé, A.-G., Corvol, J.-C., Tassin, J.-P., Girault, J.-A., & Hervé, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011809 · Cited by 59
“Yet little is known about the intracellular signaling events triggered by receptor activation in the prefrontal cortex and about their implications in the functional effects of psychostimulants (Svenningsson et al., 2003).”
BackgroundPozzi, L., Baviera, M., Sacchetti, G., Calcagno, E., Balducci, C., Invernizzi, R. W., & Carli, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2010.11.060 · Cited by 49
Interaction between LSD and dopamine D2/3 binding sites in pig brain
Minuzzi, L., Nomikos, G. G., Wade, M. R., Jensen, S. B., Olsen, A. K., & Cumming, P. (2005) · Synapse · doi:10.1002/syn.20141 · Cited by 26
Self-citationClassical-quantum interfaces in living neural tissue supporting conscious functions
(2020) · Advances in Quantum Chemistry · doi:10.1016/bs.aiq.2020.08.002 · Cited by 6
Metadata
- Authors
- Svenningsson, P., Tzavara, E. T., Carruthers, R., Rachleff, I., Wattler, S., Nehls, M., McKinzie, D. L., Fienberg, A. A., Nomikos, G. G., & Greengard, P.
- Venue
- Science
- Published
- 2003-11-21
- Volume
- 302
- Issue
- 5649
- Pages
- 1412-1415
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086048722
- Cited by
- 314
- References
- 19
- FWCI
- 15.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.